{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:31:47Z","timestamp":1790829107378,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-026-06970-y","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:55:12Z","timestamp":1776992112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of vosoritide in children with achondroplasia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3645-3154","authenticated-orcid":false,"given":"Ghaidaa A.","family":"Alfaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakeema A.","family":"Alfaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar","family":"Adel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma B.","family":"AlGadeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"6970_CR1","unstructured":"Chamarthi VS, Chamarthi S, Karsonovich T. Achondroplasia (2025)\u00a0Achondroplasia. StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559263\/"},{"issue":"1","key":"6970_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0972-6","volume":"14","author":"RM Pauli","year":"2019","unstructured":"Pauli RM (2019) Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis 14(1):1","journal-title":"Orphanet J Rare Dis"},{"key":"6970_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/boneres.2014.3","volume":"2","author":"N Su","year":"2014","unstructured":"Su N, Jin M, Chen L (2014) Role of FGF\/FGFR signaling in skeletal development and homeostasis: learning from mouse models. Bone Res 2:14003","journal-title":"Bone Res"},{"issue":"1","key":"6970_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M et al (2020) FGF\/FGFR signaling in health and disease. Signal Transduct Target Ther 5(1):181","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"6970_CR5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/dmcn.15194","volume":"64","author":"JA Armstrong","year":"2022","unstructured":"Armstrong JA, Pacey V, Tofts LJ (2022) Medical complications in children with achondroplasia. Dev Med Child Neurol 64(8):989\u2013997","journal-title":"Dev Med Child Neurol"},{"issue":"21","key":"6970_CR6","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.1080\/09638288.2021.1963853","volume":"44","author":"C Constantinides","year":"2022","unstructured":"Constantinides C, Landis SH, Jarrett J, Quinn J, Ireland PJ (2022) Quality of life, physical functioning, and psychosocial function among patients with achondroplasia: a targeted literature review. Disabil Rehabil 44(21):6166\u20136178","journal-title":"Disabil Rehabil"},{"issue":"1","key":"6970_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s13023-021-01971-6","volume":"16","author":"V Cormier-Daire","year":"2021","unstructured":"Cormier-Daire V, AlSayed M, Ben-Omran T, de Sousa SB, Boero S, Fredwall SO et al (2021) The first European consensus on principles of management for achondroplasia. Orphanet J Rare Dis 16(1):333","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"6970_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000446958","volume":"86","author":"M Miccoli","year":"2016","unstructured":"Miccoli M, Bertelloni S, Massart F (2016) Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis. Horm Res Paediatr 86(1):27\u201334","journal-title":"Horm Res Paediatr"},{"key":"6970_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115573","author":"W Wrobel","year":"2021","unstructured":"Wrobel W, Pach E, Ben-Skowronek I (2021) Advantages and disadvantages of different treatment methods in achondroplasia: a review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22115573","journal-title":"Int J Mol Sci"},{"issue":"12","key":"6970_CR10","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1515\/jpem-2020-0298","volume":"33","author":"M Del Pino","year":"2020","unstructured":"Del Pino M, Fano V, Adamo P (2020) Growth in achondroplasia, from birth to adulthood, analysed by the JPA-2 model. J Pediatr Endocrinol Metab 33(12):1589\u20131595","journal-title":"J Pediatr Endocrinol Metab"},{"key":"6970_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23115916","author":"E Rintz","year":"2022","unstructured":"Rintz E, W\u0119grzyn G, Fujii T, Tomatsu S (2022) Molecular mechanism of induction of bone growth by the C-type natriuretic peptide. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23115916","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6970_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S2352-4642(23)00265-1","volume":"8","author":"R Savarirayan","year":"2024","unstructured":"Savarirayan R, Wilcox WR, Harmatz P, Phillips J III, Polgreen LE, Tofts L et al (2024) Vosoritide therapy in children with achondroplasia aged 3\u201359 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child Adolesc Health 8(1):40\u201350","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"6970_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa1813446","volume":"381","author":"R Savarirayan","year":"2019","unstructured":"Savarirayan R, Irving M, Bacino CA, Bostwick B, Charrow J, Cormier-Daire V et al (2019) C-Type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med 381(1):25\u201335","journal-title":"N Engl J Med"},{"key":"6970_CR14","unstructured":"Inc BP. U.S. Food and Drug Administration approves BioMarin\u2019s VOXZOGO\u00ae (vosoritide) for children under 5 years with achondroplasia. Available from: https:\/\/www.prnewswire.com\/news-releases\/us-food-and-drug-administration-approves-biomarins-voxzogo-vosoritide-for-children-under-5-years-with-achondroplasia-301963505.html."},{"key":"6970_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"1","key":"6970_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1542\/peds.109.1.45","volume":"109","author":"CL Ogden","year":"2002","unstructured":"Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R et al (2002) Centers for disease control and prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109(1):45\u201360","journal-title":"Pediatrics"},{"key":"6970_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"6970_CR18","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"key":"6970_CR19","doi-asserted-by":"publisher","unstructured":"Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z (eds) (2024) JBI manual for evidence synthesis. JBI.\u00a0https:\/\/doi.org\/10.46658\/JBIMES-24-01","DOI":"10.46658\/JBIMES-24-01"},{"key":"6970_CR20","doi-asserted-by":"publisher","unstructured":"Dai W, Lin A, Yi Y, Zhou C, Zhang J, Wang S, Sun M, Luo P (2026) Onlinemeta: A web server for meta-analysis based on shiny framework. Curr Radiopharm\u00a019(2).\u00a0https:\/\/doi.org\/10.1016\/j.craph.2025.100023","DOI":"10.1016\/j.craph.2025.100023"},{"issue":"11","key":"6970_CR21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558","journal-title":"Stat Med"},{"issue":"7109","key":"6970_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"key":"6970_CR23","unstructured":"McMaster University EP. GRADEpro GDT: GRADEpro Guideline Development Tool [Software] 2023 [Available from: https:\/\/gradepro.org"},{"key":"6970_CR24","doi-asserted-by":"crossref","unstructured":"Shimada T, Nakayama H, Ueda I, Ishimi T, Yamada C, Nakano Y et al (2025) Real-world safety and age-dependent effectiveness of vosoritide in achondroplasia: a single-center retrospective analysis of transition from growth hormone to vosoritide. 117722.","DOI":"10.1016\/j.bone.2025.117722"},{"key":"6970_CR25","doi-asserted-by":"publisher","unstructured":"Allegri AEM, Bedeschi MF, Bocchi MB, Camurri V, Gonfiantini MV, Leoni C, Mariani M, Palmacci O, Porro M, Riganti S, Tedesco C, Rinaldi B, Scarano E, Schiavariello C, Selicorni A, Stagi S, Verdoni F, Zampino G, Maghnie M, Onesimo R (2025) Integrating vosoritide therapy with limb surgery in paediatric patients with achondroplasia: real-life experiences. Orphanet J Rare Dis 20(1):369.\u00a0\nhttps:\/\/doi.org\/10.1186\/s13023-025-03853-7","DOI":"10.1186\/s13023-025-03853-7"},{"issue":"1","key":"6970_CR26","first-page":"185","volume":"19","author":"JJL Clinton","year":"2025","unstructured":"Clinton JJL, Magalhaes TSPC, Bordallo AP, Collett-Solberg PFJ (2025) Hypertrichosis associated with the use of C-type natriuretic peptide analogue: a case report. JoMCR 19(1):185","journal-title":"JoMCR"},{"key":"6970_CR27","doi-asserted-by":"publisher","unstructured":"Cormier-Daire V, Edouard T, Isidor B, Mukherjee S, Pimenta JM, Rossi M, Schaefer E, Sigaudy S, Baujat G (2025) Real-world safety and effectiveness of vosoritide in children with achondroplasia: French Early Access Program. Horm Res in Paediatr. Advance online publication.\u00a0https:\/\/doi.org\/10.1159\/000543743","DOI":"10.1159\/000543743"},{"key":"6970_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.64054","author":"P Ireland","year":"2025","unstructured":"Ireland P, Carroll T, Pendlebury E, Weston E, Munns C (2025) Functional change in a child with achondroplasia following 12 months treatment with vosoritide-a case report. Am J Med Genet A. https:\/\/doi.org\/10.1002\/ajmg.a.64054","journal-title":"Am J Med Genet A"},{"key":"6970_CR29","doi-asserted-by":"publisher","unstructured":"Ireland PJ, Carroll T, Cotton Z, Ludwig K, Weston E, Munns CF et al (2026) Functional change in three adolescents with achondroplasia following 12 months treatment with vosoritide\u2014A case series. J Paediatr Child Health\u00a062(1):131\u2013134.\u00a0 https:\/\/doi.org\/10.1111\/jpc.70232","DOI":"10.1111\/jpc.70232"},{"issue":"5","key":"6970_CR30","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf041","volume":"9","author":"S Reincke","year":"2025","unstructured":"Reincke S, Semler O, Jungh\u00e4nel-Welzing S, Stasek S, Rehberg M, Pfeiffer E et al (2025) Real-world outcome of vosoritide treatment in children with achondroplasia: a 12-month retrospective observational study. J Endocr Soc 9(5):bvaf041","journal-title":"J Endocr Soc"},{"key":"6970_CR31","doi-asserted-by":"publisher","unstructured":"Rua IB, Silva I, Beger C A et al (2025) Real-world safety and effectiveness of vosoritide in achondroplasia: results from a single center in Portugal.\u00a0Adv Ther 42:3726\u20133742. https:\/\/doi.org\/10.1007\/s12325-025-03223-6","DOI":"10.1007\/s12325-025-03223-6"},{"key":"6970_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/BPO.0000000000002980","author":"K Sawamura","year":"2025","unstructured":"Sawamura K, Kitoh H, Kamiya Y, Mishima K, Matsushita M, Imagama S (2025) Changes in the alignment of the spine and lower limb in children with achondroplasia treated with vosoritide: a single-center, 1-year follow-up prospective study. J Pediatr Orthop. https:\/\/doi.org\/10.1097\/BPO.0000000000002980","journal-title":"J Pediatr Orthop"},{"issue":"5","key":"6970_CR33","volume":"16","author":"A Nishioka","year":"2024","unstructured":"Nishioka A, Adachi N, Tanaka H, Oda Y (2024) Two cases of cardiovascular adverse events following subcutaneous vosoritide injection in early infancy. Cureus 16(5):e59695","journal-title":"Cureus"},{"issue":"10252","key":"6970_CR34","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","volume":"396","author":"R Savarirayan","year":"2020","unstructured":"Savarirayan R, Tofts L, Irving M, Wilcox W, Bacino CA, Hoover-Fong J et al (2020) Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet 396(10252):684\u2013692","journal-title":"Lancet"},{"issue":"12","key":"6970_CR35","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.gim.2022.08.015","volume":"24","author":"R Savarirayan","year":"2022","unstructured":"Savarirayan R, Irving M, Harmatz P, Delgado B, Wilcox WR, Philips J et al (2022) Growth parameters in children with achondroplasia: a 7-year, prospective, multinational, observational study. Genet Med 24(12):2444\u20132452","journal-title":"Genet Med"},{"key":"6970_CR36","doi-asserted-by":"crossref","unstructured":"Hoover-Fong J, McGready J, Schulze K, Alade AY, Scott CI, JAjomg PA (2017) A height-for-age growth reference for children with achondroplasia: expanded applications and comparison with original reference data. 173(5):1226\u201330","DOI":"10.1002\/ajmg.a.38150"},{"key":"6970_CR37","doi-asserted-by":"publisher","unstructured":"St Clair-Jones A, Prignano F, Goncalves J et al (2020)\u00a0Understanding and minimising injection-site pain following subcutaneous administration of biologics: A narrative review. Rheumatol Ther 7:741\u2013757. https:\/\/doi.org\/10.1007\/s40744-020-00245-0","DOI":"10.1007\/s40744-020-00245-0"},{"issue":"5","key":"6970_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41574-024-01074-9","volume":"21","author":"R Savarirayan","year":"2025","unstructured":"Savarirayan R, Hoover-Fong J, Ozono K, Backeljauw P, Cormier-Daire V, DeAndrade K et al (2025) International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia. Nat Rev Endocrinol 21(5):314\u2013324","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"6970_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.11.019","volume":"6","author":"R Savarirayan","year":"2025","unstructured":"Savarirayan R, Irving M, Wilcox WR, Bacino CA, Hoover-Fong JE, Harmatz P et al (2025) Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study. Med 6(5):100566","journal-title":"Med"},{"issue":"12","key":"6970_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2024.101274","volume":"26","author":"R Savarirayan","year":"2024","unstructured":"Savarirayan R, Irving M, Wilcox WR, Bacino CA, Hoover-Fong JE, Harmatz P et al (2024) Persistent growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health-related quality of life. Genet Med 26(12):101274","journal-title":"Genet Med"},{"key":"6970_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2023.117275","volume":"87","author":"E Dardenne","year":"2023","unstructured":"Dardenne E, Ishiyama N, Lin T-A, Lucas MC (2023) Current and emerging therapies for achondroplasia: the dawn of precision medicine. Bioorg Med Chem 87:117275","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"6970_CR42","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJMoa2411790","volume":"392","author":"R Savarirayan","year":"2025","unstructured":"Savarirayan R, De Bergua JM, Arundel P, Salles JP, Saraff V, Delgado B et al (2025) Oral infigratinib therapy in children with achondroplasia. N Engl J Med 392(9):865\u2013874","journal-title":"N Engl J Med"},{"issue":"6","key":"6970_CR43","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/jbmr\/zjae051","volume":"39","author":"B Demuynck","year":"2024","unstructured":"Demuynck B, Flipo J, Kaci N, Dambkowski C, Paull M, Muslimova E et al (2024) Low-dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model. J Bone Miner Res 39(6):765\u2013774","journal-title":"J Bone Miner Res"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-06970-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-06970-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-06970-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:02:40Z","timestamp":1780120960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-06970-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6970"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-06970-y","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}